🏛️ Verified NIH Record • Updated 2025-02-03
A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody (NCT05662397)
An Open Label, Phase 1/2 Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Advanced Solid Tumors
🔵 Active, Not Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic Sponsor: HotSpot Therapeutics, Inc
🩺 Plain-English Summary (8th-Grade Level)
This is a Phase 1/2 study of HST-1011, a CBL-B inhibitor, being developed for the treatment of patients with advanced solid tumors, who relapsed while on or are refractory to approved anti-PD(L)1 therapies or other standard of care.
Who can join: Review the eligibility criteria below.
Location: Florida Cancer Specialists — Sarasota, Florida
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (14 Sites)
- Florida Cancer Specialists — Sarasota, Florida
- Comprehensive Cancer Centers of Nevada — Las Vegas, Nevada
- Memorial Sloan Kettering Cancer Center — New York, New York
- Montefiore Einstein Comprehensive Cancer Center — The Bronx, New York
- Providence Cancer Institute of Oregon — Portland, Oregon
- Abramson Cancer Center — Philadelphia, Pennsylvania
- University of Pittsburgh (UPMC), Hillman Cancer Center — Pittsburgh, Pennsylvania
- The University of Texas MD Anderson Cancer Center — Houston, Texas
- University of Ottawa — Ottawa, Ontario
- Princess Margaret Cancer Center — Toronto, Ontario
- NEXT Oncology Barcelona IOB Hospital Quirónsalud — Barcelona,
- Clínica Universidad de Navarra — Madrid,
- NEXT Oncology Hospital Universitario Quirónsalud Madrid — Madrid,
- Clínica Universidad de Navarra (Pamplona) — Pamplona,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
- 💵 Compensation indicated: In Phase 1 patients will receive HST-1011 as either monotherapy (Parts A1 and A2) or in combination with the anti-PD1 antibody, cemiplimab (Part B1 and B2).
More studies in Solid Tumor, Adult
- First-in-Human Study of ICT01 in Patients With Advanced Cancer — Gilbert, Arizona
- A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors — Los Angeles, California
- A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors — Los Angeles, California
- Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab — Los Angeles, California
- Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors — San Francisco, California
Explore by condition: All Solid Tumor, Adult clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.